Founded in 1985, Innogenetics has its headquarters in Belgium (Gent); sales affiliates are located in France, Germany, Italy, Spain and the USA.
The Belgian biotechnology multinational Innogenetics is pursuing a twofold growth strategy, i.e. Developing innovative therapies in the fields of hepatitis C, immune disorders, and tissue repair; Strengthening its position in the field of high value-added diagnostics, focusing on infectious diseases, neurodegeneration, and genetic predisposition testing.
The company's ordinary shares have been listed on NASDAQ Europe since November 1996. The company asked a dual listing on Euronext in order to increase its visibility on the Belgian, Dutch, French, Portuguese and other European capital markets. In this way, Innogenetics aims at gaining an easier and more seamless access to both retail and institutional investors.
At the end of the first trading day the price closed at EUR 10.63 bringing the total Market capitalisation of Innogenetics at EUR 269,764,664. On the electronic order book, a total of 12,022 shares were traded amounting to a turnover of EUR 128 thousand.
The company Innogenetics is classified under:
The Economic Group 40: "Non Cyclical Consumer goods"
The Economic Sector 48: "Pharmaceuticals & Biotechnology"
The Economic Sub-sector 482: "Biotechnology"
Innogenetics trades on the NSC platform under the following codes:
Stock Code: INNX
Isin Code: BE0160220738
SVM Code: 160220.73
As from December 11, Innogenetics will be included in the NextEconomy segment, the segment dedicated to companies belonging to the new technology sectors. Subsequently as from December 12, Innogenetics will also integrate the NextEconomy index, thus joining a circle of enterprises wanting to increase their visibility towards investors by committing themselves to respect additional rules for financial communication and accountability.
Innogenetics is the 14th IPO on the Euronext regulated markets (i.e. the Marché Libre of Euronext Paris not included) since the beginning of the year.
